The test evaluates the predisposition of an individual to develop breast and ovarian cancer.
BRCA 1 and BRCA 2 genes
Breast cancer is the most common cancer in women. It is estimated that approximately 7-8% of patients with breast cancer have a inherited genetic predisposition. Mutations of BRCA1 and BRCA2 genes are associated to hereditary breast cancer, these genes are also associated with an increased risk of developing ovarian cancer and other cancers.
Why it’s done?
The analysis of the BRCA1 and BRCA2 genes is suitable for women with a family history of breast or ovarian cancer, women with breast cancer in young age, women with bilateral breast cancer and some histological types of cancer (eg. Triple negative, multicentric). Discovery of a BRCA1 or BRCA2 mutation helps establishing the proper prevention and surveillance lines, with a risk reduction through medical and/or surgical treatments. The identification of these gene alterations in young individuals leads to a reduction in mortality and also morbidity. Indeed these individuals are not normally included in population screening: if they are mutation carriers, they have a high risk of developing breast or ovarian cancer. Surveillance programs can significantly reduce mortality and it is possible to reduce morbidity through prophylactic surgery.
Microgenomics genetic analysis is based on the new NGS technology – Next Generation Sequencing, through which you can perform complete and thorough analysis of your BRCA1 and BRCA2 genes. The test does not require any complimentary analysis: it allows the identification of small DNA sequence variations as well as broaden gene rearrangements. This reduces the cost of the analysis and the reporting time; instead of the BRCA genes analysis carried out through two distinct tests, sequencing analysis and MLPA test. Microgenomics test is extremely accurate: the sensitivity and specificity are over 99%. To perform the test you simply need a blood sample taken.
For informations about the collection kit and shipment of samples, to receive analysis application forms or further clarifications write us.